IP Library Granted Patent US 11,220,491
Granted Patent B2
US 11,220,491 · App. 16/382,891 · Granted Jan 11, 2022

Photoprotective compositions containing

Inventors: Michael Einziger (Malibu, CA); Ann Marie Simpson (Malibu, CA)
Assignee: Versicolor Technologies, LLC
C07D403/06A61K8/494A61K8/4973A61K31/404A61K31/407A61K31/55A61Q19/02C07D405/06C07D487/04C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,220,491
App. No.
16/382,891
Granted
Jan 11, 2022
Kind
B2
Abstract

The present invention relates to compounds, compositions, and methods for modulating skin pigmentation and treating or preventing UV-induced skin damage, erythema, aging of the skin, sunburn, and hyperpigmentation in a subject. The compounds, compositions, and methods of the present invention generally involve Malassezia -derived compounds, including malassezin and indirubin, and/or chemical analogs thereof. Other applications of the compounds and compositions disclosed herein include, but are not limited to, improving hyperpigmentation caused by a hyperpigmentation disorder, inducing melanocyte apoptosis, and modulating arylhydrocarbon receptor (AhR) activity, melanogenesis, melanin production, melanosome biogenesis, melanosome transfer, melanocyte activity, and melanin concentration.

Claims (121)

1. A compound having the structure of the following formula:

wherein:

X is selected from the group consisting of NR 14 and O;

Y is CR 5 R 6 , O, or NR 15 ;

R 1 , R 2 , R 3 , R 4 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from the group consisting of hydrogen, halogen, CN, hydroxyl, R 16 , and OR 16 ,

R 13 is hydrogen,

R 14 and R 15 are independently hydrogen or R 16 ;

R 5 and R 6 are independently selected from the group consisting of hydrogen, hydroxyl, OR 16 , R 16 , and C 3-6 cycloalkyl, or R 5 and R 6 combine to form an oxo (═O) group or a C 3-6 cycloalkyl;

R 12 is COR a ;

each R 16 is independently formyl, C 1-9 alkyl, C 2-9 alkenyl, or C 2-9 alkynyl; and,

R a is selected from the group consisting of hydrogen, hydroxyl, and OR 16 ;

wherein:

if R a is hydrogen, Y is CR 5 R 6 , and R 14 is hydrogen, then

R 5 is selected from the group consisting of hydroxyl, OR 16 , and C 3-6 cycloalkyl, or R 5 and R 6 combine to form a C 3-6 cycloalkyl;

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , having the following structure:

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

3. A compound having the structure of the following formula:

wherein:

X is selected from the group consisting of NR 14 and O;

R 1 , R 2 , R 3 , R 4 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from the group consisting of hydrogen, halogen, CN, hydroxyl, R 16 , and OR 16 ,

R 13 is hydrogen,

R 14 is hydrogen or R 16 ;

R 12 is COR a ;

each R 16 is independently formyl, C 1-9 alkyl, C 2-9 alkenyl, or C 2-9 alkynyl;

R a is selected from the group consisting of hydrogen, hydroxyl, and OR 16 ;

Y is CR 5 R 6 ;

R 5 is hydrogen, and R 6 is C 3-6 cycloalkyl, or O—(C 1-4 alkyl);

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein each of R 1 , R 2 , R 3 , R 4 , R 7 , R 8 , R 9 , R 10 , and R 11 is hydrogen,

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

5. The compound of claim 3 ,

wherein:

X is NH;

each of R 1 , R 3 , R4, R 7 , R 8 , R 9 , R 10 , and R 11 is hydrogen; and

R 2 is hydrogen or C 1-4 alkyl;

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

6. The compound according to claim 1 , wherein the compound is:

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

7. A composition comprising a compound, the compound having the structure of the following formula:

wherein:

X is selected from the group consisting of NR 14 and O;

Y is CR 5 R 6 , O, or NR 15 ;

R 1 , R 2 , R 3 , R 4 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from the group consisting of hydrogen, halogen, CN, hydroxyl, R 16 , and OR 16 ;

R 13 is hydrogen,

R 14 and R 15 are independently hydrogen or R 16 ;

R 5 and R 6 are independently selected from the group consisting of hydrogen, hydroxyl, OR 16 , R 16 , and C 3-6 cycloalkyl, or R 5 and R 6 combine to form an oxo (═O) group or a C 3-6 cycloalkyl;

R 12 is COR a ;

each R 16 is independently formyl, C 1-9 alkyl, C 2-9 alkenyl, or C 2-9 alkynyl; and,

R a is selected from the group consisting of hydrogen, hydroxyl, and OR 16 ;

wherein:

if R a is hydrogen, Y is CR 5 R 6 , and R 14 is hydrogen, then

R 5 is selected from the group consisting of hydroxyl, OR 16 , and C 3-6 cycloalkyl, or R 5 and R 6 combine to form a C 3-6 cycloalkyl;

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

8. The composition of claim 7 , wherein the composition comprises a compound having the following structure:

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

9. A composition comprising a compound, the compound having the structure of the following formula:

wherein:

X is selected from the group consisting of NR 14 and O;

R 1 , R 2 , R 3 , R 4 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from the group consisting of hydrogen, halogen, CN, hydroxyl, R 16 , and OR 16 ,

R 13 is hydrogen,

R 14 is hydrogen or R 16 ;

R 12 is COR a ;

each R 16 is independently formyl, C 1-9 alkyl, C 2-9 alkenyl, or C 2-9 alkynyl;

R a is selected from the group consisting of hydrogen, hydroxyl, and OR 16 ;

Y is CR 5 R 6 ;

R 5 is hydrogen, and R 6 is C 3-6 cycloalkyl, or O—(C 1-4 alkyl);

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

10. The composition of claim 7 , wherein each of R 1 , R 2 , R 3 , R 4 , R 7 , R 8 , R 9 , R 10 , and R 11 is hydrogen.

11. The composition of claim 9 ,

wherein:

is NH;

each of R 1 , R 3 , R 4 , R 7 , R 8 , R 9 , R 10 , and R 11 is hydrogen; and

R 2 is hydrogen or C 1-4 alkyl.

12. A composition according to claim 7 , wherein the compound is:

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

13. The compound of claim 1 , wherein X is NH;

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

14. The compound of claim 2 , wherein X is NH;

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

15. The compound of claim 3 , wherein X is NH;

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

16. The compound of claim 4 , wherein X is NH;

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

17. The compound of claim 5 , wherein R 12 is CO(—O—C 1-4 alkyl);

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

18. The compound of claim 13 , wherein R 12 is CO(—O—C 1-4 alkyl);

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

19. The compound of claim 14 , wherein R 12 is CO(—O—C 1-4 alkyl);

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

20. The compound of claim 15 , wherein R 12 is CO(—O—C 1-4 alkyl);

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

21. The compound of claim 16 , wherein R 12 is CO(—O—C 1-4 alkyl);

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

22. The compound of claim 5 , wherein Y is CH(C 3 H 5 );

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

23. The compound of claim 17 , wherein Y is CH(C 3 H 5 );

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

24. The compound of claim 18 , wherein Y is CH(C 3 H 5 );

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

25. The compound of claim 19 , wherein Y is CH(C 3 H 5 );

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

26. The compound of claim 20 , wherein Y is CH(C 3 H 5 );

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

27. The compound of claim 21 , wherein Y is CH(C 3 H 5 );

or a hydrate or cosmetically or pharmaceutically acceptable salt thereof.

28. The composition of claim 7 , wherein X is NH.

29. The composition of claim 8 , wherein X is NH.

30. The composition of claim 9 , wherein X is NH.

31. The composition of claim 10 , wherein X is NH.

32. The composition of claim 11 , wherein R 12 is CO(—O—C 1-4 alkyl).

33. The composition of claim 28 , wherein R 12 is CO(—O—C 1-4 alkyl).

34. The composition of claim 29 , wherein R 12 is CO(—O—C 1-4 alkyl).

35. The composition of claim 30 , wherein R 12 is CO(—O—C 1-4 alkyl).

36. The composition of claim 31 , wherein R 12 is CO(—O—C 1-4 alkyl).

37. The composition of claim 11 , wherein Y is CH(C 3 H 5 ).

38. The composition of claim 32 , wherein Y is CH(C 3 H 5 ).

39. The composition of claim 33 , wherein Y is CH(C 3 H 5 ).

40. The composition of claim 34 , wherein Y is CH(C 3 H 5 ).

41. The composition of claim 35 , wherein Y is CH(C 3 H 5 ).

42. The composition of claim 36 , wherein Y is CH(C 3 H 5 ).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2019
From: EINZIGER, MICHAEL; SIMPSON, ANN MARIE
To: VERSICOLOR TECHNOLOGIES, LLC
Reel/Frame 050959/0905 →
Continuity (7)
Provisional Application 62656769 · Apr 12, 2018
Provisional Application 62668007 · May 7, 2018
Provisional Application 62685800 · Jun 15, 2018
Provisional Application 62686912 · Jun 19, 2018
Provisional Application 62722412 · Aug 24, 2018
Provisional Application 62742657 · Oct 8, 2018
Related Publication 20190345140A1 · Nov 14, 2019
Cited By (2)
US 12,458,577 US 12,497,385